Responses
Immunotherapy biomarkers
Original research
A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses
Compose a Response to This Article
Other responses
No responses have been published for this article.